HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Bata, M. S. Articles by Schwartz, J. Search for Related Content PubMed PubMed Citation Articles by Bata, M. S. Articles by Schwartz, J. Social Bookmarking                         What's this?

Delay of Ovulation by Meloxicam in Healthy Cycling Volunteers: A Placebo-Controlled, Double-blind, Crossover Study

From the Department of Obstetrics and Gynecology (Dr Bata, Dr Al-Ramahi) and the Department of Pharmacology (Dr Salhab, Dr Gharaibeh), Faculty of Medicine, University of Jordan, Amman, Jordan; and CONRAD, Eastern Virginia Medical School, Arlington, Virginia (Dr Schwartz).

This study aimed to assess the effect of meloxicam on female ovulation. Twenty consented fertile females were monitored for 4 menstrual cycles: a baseline cycle, 2 treatment cycles, and a washout cycle between treatment cycles. In the first cycle visit, transvaginal ultrasound was performed, a blood sample for progesterone and meloxicam analysis was withdrawn, and volunteers were given a luteinizing hormone (LH) urine test kit and meloxicam or placebo. Volunteers started the treatment on the following day and asked to return the day the LH kit was positive to detect the dominant follicle. At subsequent visits, transvaginal ultrasound and progesterone and meloxicam levels were investigated. Compared to placebo, a 5-day delay in follicle rupture, a 55.7% increase in the mean maximum follicle diameter, and 33.5% decrease of plasma progesterone level were observed in the meloxicam-treated group. Such demonstrated meloxicam effects were reversed in participants who were randomized to meloxicam first and then placebo. Only minor side effects were reported by volunteers during the course of treatment. It is concluded that meloxicam resulted in a reversible delay of ovulation, an increase in follicular diameter, and a decrease in plasma progesterone level.

Key Words: Follicle rupture • follicle size • meloxicam • ultrasound • progesterone

Address for reprints: Dr. A. S. Salhab, Department of Pharmacology, Faculty of Medicine, University of Jordan, Amman, Jordan; e-mail: Assalhab{at}ju.edu.jo.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Jesam, A. M. Salvatierra, J. L. Schwartz, and H. B. Croxatto Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception Hum. Reprod., February 1, 2010; 25(2): 368 - 373. [Abstract] [Full Text] [PDF]

				K. E. Hester, M. J.K. Harper, and D. M. Duffy Oral administration of the cyclooxygenase-2 (COX-2) inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception Hum. Reprod., February 1, 2010; 25(2): 360 - 367. [Abstract] [Full Text] [PDF]

				K Vincent Chronic pelvic pain in women Postgrad. Med. J., January 1, 2009; 85(999): 24 - 29. [Abstract] [Full Text] [PDF]